2021
DOI: 10.21203/rs.3.rs-506178/v1
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Effects of artificial cycles with and without gonadotropin-releasing hormone agonist pretreatment on frozen embryo transfer outcomes in patients with adenomyosis

Abstract: Gonadotropin-releasing hormone agonist(GnRH-a) is generally added to improve pregnancy outcomes of adenomyosis based hormone replacement therapy cycle. Our objective in this study is to investigate whether adding GnRH-a can obtain better pregnancy outcomes. In this retrospective analysis, a total of 341 patients with adenomyosis complicated in vitro fertilization-embryo transfer(IVF-ET) of the frozen embryo transfer (FET). The control group was only treated by hormone replacement therapy cycles to prepare emdo… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 17 publications
0
2
0
Order By: Relevance
“…In contrast, our results showed that long-acting GnRH agonist pretreatment before FET in HRT cycle following GnRH antagonist protocol didn’t reach a higher clinical pregnancy rate, live birth rate and CLBR. Previous studies exhibited similar results, which found that long-acting GnRH agonist based on the HRT cycle may not increase the rate of clinical pregnancy or live birth [ 27 ]. Severity degree of adenomyosis is a quite important factor which impacts pregnancy outcomes.…”
Section: Discussionmentioning
confidence: 63%
“…In contrast, our results showed that long-acting GnRH agonist pretreatment before FET in HRT cycle following GnRH antagonist protocol didn’t reach a higher clinical pregnancy rate, live birth rate and CLBR. Previous studies exhibited similar results, which found that long-acting GnRH agonist based on the HRT cycle may not increase the rate of clinical pregnancy or live birth [ 27 ]. Severity degree of adenomyosis is a quite important factor which impacts pregnancy outcomes.…”
Section: Discussionmentioning
confidence: 63%
“…One recent retrospective cohort demonstrated no difference in outcome using GnRH-agonist pretreatment in frozen embryo transfer; however, this cohort had a wide range of pretreatment ranging from one dose of leuprolide acetate in the preceding cycle up to several monthly injections of a GnRH agonist prior to transfer [34 ▪ ]. Another retrospective trial found lower live birth rate and clinical pregnancy rate in patients who underwent GnRH-agonist pretreatment (up to three monthly doses) versus no pretreatment in a fresh transfer cycle [35].…”
Section: Treatment Of Adenomyosis For Patients With Infertilitymentioning
confidence: 96%